Trial Profile
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs IMA-203 (Primary) ; Nivolumab (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Skin cancer; Solid tumours; Synovial sarcoma; Triple negative breast cancer; Uterine cancer; Uveal melanoma
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Acronyms ACTengine
- Sponsors Immatics US
- 02 Nov 2023 Planned number of patients changed from 186 to 270.
- 23 Sep 2023 Results assessing the safety and anti -tumor activity of IMA203 TCR -Tin patients with recurrent/refractory solid tumors, presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
- 21 Aug 2023 Planned number of patients changed from 172 to 186.